UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~February 28, 2018.~~

August 31, 2022.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to

Commission file number

0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)


Michigan		38-2367843
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

(517)

372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:


Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.16 par value per share	NEOG	NASDAQ Global Select Market

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation

S-T (§

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or a~~non-accelerated~~ ~~filer (see definition~~an emerging growth company. See the definitions of ~~“accelerated filer and large~~“large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange ~~Act):~~

Act.


Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	~~☐ (Do not check if a smaller reporting company)~~	~~Smaller reporting company~~	☐	Smaller Reporting Company	☐

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended ~~transaction~~transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act): YES ☐ NO ☒

As of ~~February 28, 2018,~~August 31, 2022 there were ~~51,583,085~~107,837,730 shares of Common Stock outstanding.

Table of Contents

PART I – FINANCIAL INFORMATION

~~Item 1.~~

~~Interim Consolidated Financial Statements~~

Item 1. Interim Consolidated Financial Statements

Neogen Corporation and Subsidiaries

Consolidated Balance ~~Sheet~~

Sheets (unaudited)

(in thousands, except share and

per share amounts)

   February 28,
2018 May 31,
2017
   (Unaudited) (Audited)
Assets

Current Assets

Cash and cash equivalents
   $ 82,066 $ 77,567
Marketable securities (at fair value, which approximates cost)
   110,089 66,068
Accounts receivable, less allowance of $1,750 and $2,000
   73,209 68,576
Inventories, net
   77,506 73,144
Prepaid expenses and other current assets
   9,334 7,606


Total Current Assets
   352,204 292,961
Property and Equipment, net
   72,514 61,748
Other Assets

Goodwill
   99,478 104,759
Othernon-amortizable intangible assets
   15,011 14,323
Customer-based intangibles, net of accumulated amortization of $23,846 and $20,846 at February 28, 2018 and May 31, 2017
   33,518 35,983
Othernon-current assets, net of accumulated amortization of $11,893 and $9,931 at February 28, 2018 and May 31, 2017
   22,876 18,635


Total Assets
   $ 595,601 $ 528,409


Liabilities and Equity

Current Liabilities

Accounts payable
   $ 19,654 $ 16,244
Accrued compensation
   5,469 5,002
Income taxes
   960 936
Other accruals
   11,210 13,820


Total Current Liabilities
   37,293 36,002
Deferred Income Taxes
   11,400 17,048
Non-Current Liabilities
   4,973 3,602


Total Liabilities
   53,666 56,652
Commitments and Contingencies (note 9)

Equity

Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding
   —   —
Common stock, $0.16 par value, 60,000,000 shares authorized, 51,583,085 and 50,932,489 shares issued and outstanding at February 28, 2018 and May 31, 2017, respectively
   8,253 8,149
Additionalpaid-in capital
   197,246 174,742
Accumulated other comprehensive loss
   (5,303 ) (7,203 )
Retained earnings
   341,459 295,926


Total Neogen Corporation Stockholders’ Equity
   541,655 471,614
Non-controlling interest
   280 143


Total Equity
   541,935 471,757


Total Liabilities and Equity
   $ 595,601 $ 528,409


	August 31,			May 31,
	2022			2022
Assets
Current Assets
Cash and cash equivalents	$	107,098		$	44,473
Marketable securities		240,613			336,578
Accounts receivable, net of allowance of $1,800 and $1,650 at August 31, 2022 and May 31, 2022, respectively		93,112			99,674
Inventories		129,039			122,313
Prepaid expenses and other current assets		38,045			23,760

Total Current Assets		607,907			626,798
Net Property and Equipment		121,021			110,584
Other Assets
Right of use assets		2,834			3,184
Goodwill		140,067			142,704
Other non-amortizable intangible assets		15,182			15,397
Amortizable intangible and other assets, net of accumulated amortization of $55,201 and $55,416 at August 31, 2022 and May 31, 2022, respectively		88,239			92,106
Other non-current assets		2,155			2,156

Total Assets	$	977,405		$	992,929

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	27,002		$	34,614
Accrued compensation		8,295			11,123
Income tax payable		3,921			2,126
Deferred revenue		5,464			5,460
Other accruals		22,322			24,521

Total Current Liabilities		67,004			77,844
Deferred Income Tax Liability		15,949			17,011
Other Non-Current Liabilities		10,654			10,700

Total Liabilities		93,607			105,555
Commitments and Contingencies (note 10)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.16 par value, 120,000,000 shares authorized, 107,837,730 and 107,801,094 shares issued and outstanding at August 31, 2022 and May 31, 2022, respectively		17,254			17,248
Additional paid-in capital		312,750			309,984
Accumulated other comprehensive loss		(39,326	)		(27,769	)
Retained earnings		593,120			587,911

Total Stockholders’ Equity		883,798			887,374

Total Liabilities and Stockholders’ Equity	$	977,405		$	992,929

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Income (unaudited)

(in thousands, except per share amounts)

   Three Months Ended Nine Months Ended
   February 28, February 28,
   2018    2017 2018 2017
Revenues

Product revenues
   $ 78,142    $ 73,964 $ 244,298 $ 223,170
Service revenues
   17,750    14,421 48,667 39,577




Total Revenues
   95,892    88,385 292,965 262,747
Cost of Revenues

Cost of product revenues
   40,352    38,816 124,785 113,241
Cost of service revenues
   10,019    8,689 27,517 24,556




Total Cost of Revenues
   50,371    47,505 152,302 137,797




Gross Margin
   45,521    40,880 140,663 124,950
Operating Expenses

Sales and marketing
   17,492    15,340 52,331 45,824
General and administrative
   9,280    8,548 29,096 25,094
Research and development
   2,836    2,641 8,901 8,087




Total Operating Expenses
   29,608    26,529 90,328 79,005




Operating Income
   15,913    14,351 50,335 45,945
Other Income

Interest income
   524    271 1,322 690
Other income
   844    1,105 1,913 1,098




Total Other Income
   1,368    1,376 3,235 1,788




Income Before Taxes
   17,281    15,727 53,570 47,733
Provision for Income Taxes
   700    5,350 7,900 16,250




Net Income
   16,581    10,377 45,670 31,483
Net (Income)/Loss Attributable toNon-Controlling Interest
   5    (90 ) (70 ) (163 )




Net Income Attributable to Neogen
   $ 16,586    $ 10,287 $ 45,600 $ 31,320




Net Income Attributable to Neogen Per Share

Basic
   $ 0.32    $ 0.20 $ 0.89 $ 0.62




Diluted
   $ 0.32    $ 0.20 $ 0.88 $ 0.61


	Three Months Ended
	August 31,
	2022			2021
Revenues
Product revenues	$	106,792		$	104,013
Service revenues		25,557			24,292

Total Revenues		132,349			128,305
Cost of Revenues
Cost of product revenues		55,441			54,726
Cost of service revenues		14,638			13,571

Total Cost of Revenues		70,079			68,297

Gross Margin		62,270			60,008

Operating Expenses
Sales and marketing		23,383			20,555
General and administrative		27,944			13,383
Research and development		4,881			4,325

Total Operating Expenses		56,208			38,263

Operating Income		6,062			21,745

Other Income (Expense)
Interest income		969			203
Other expense		(372	)		(221	)

Total Other Income (Expense)		597			(18	)

Income Before Taxes		6,659			21,727
Provision for Income Taxes		1,450			4,650

Net Income	$	5,209		$	17,077


Net Income Per Share
Basic	$	0.05		$	0.16

Diluted	$	0.05		$	0.16


Weighted Average Shares Outstanding
Basic		107,837			107,490
Diluted		107,857			108,109

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated ~~Statement~~Statements of

Equity (unaudited)

(in thousands)

            Accumulated
         Additional    Other Non-
   Common Stock    Paid-in    Comprehensive Retained controlling
   Shares    Amount    Capital    Income (Loss) Earnings Interest    Total
Balance, May 31, 2017
   50,932    $ 8,149    $ 174,742    $ (7,203 ) $ 295,926 $ 143    $ 471,757
Issuance of shares under share-based compensation plan
   631    101    21,456       21,557
Issuance of shares under employee stock purchase plan
   20    3    1,048       1,051
Conversion of minority interest to retained earnings
            (67 ) 67    —
Net income for the nine months ended February 28, 2018
            45,600 70    45,670
Other comprehensive income
            1,900    1,900










Balance February 28, 2018
   51,583    $ 8,253    $ 197,246    $ (5,303 ) $ 341,459 $ 280    $ 541,935


	Common Stock				Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total
	Shares		Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total
Balance, June 1, 2022		107,801	$	17,248	$	309,984	$	(27,769	)	$	587,911	$	887,374
Exercise of options and share-based compensation expense		4		1		1,904		—			—		1,905
Issuance of shares under employee stock purchase plan		33		5		862		—			—		867
Net income for the three months ended August 31, 2022		—		—		—		—			5,209		5,209
Other comprehensive loss for the three months ended August 31, 2022		—		—		—		(11,557	)		—		(11,557	)

Balance, August 31, 2022		107,838	$	17,254	$	312,750	$	(39,326	)	$	593,120	$	883,798


	Common Stock				Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total
	Shares		Amount		Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total
Balance, June 1, 2021		107,468	$	17,195	$	294,953	$	(11,375	)	$	539,604	$	840,377
Exercise of options and share-based compensation expense		6		1		1,838		—			—		1,839
Issuance of shares under employee stock purchase plan		19		3		896		—			—		899
Net income for the three months ended August 31, 2021		—		—		—		—			17,077		17,077
Other comprehensive income for the three months ended August 31, 2021		—		—		—		(4,829	)		—		(4,829	)

Balance, August 31, 2021		107,493	$	17,199	$	297,687	$	(16,204	)	$	556,681	$	855,363

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows (unaudited)

(in thousands)

   Nine Months Ended
   February 28,
   2018 2017
Cash Flows From Operating Activities

Net Income
   $ 45,670 $ 31,483
Adjustments to reconcile net income to net cash provided from operating activities:

Depreciation and amortization
   12,682 10,691
Share-based compensation
   3,692 3,932
Excess income tax benefit from the exercise of stock options (see note 5)
   —   (3,671 )
Change in operating assets and liabilities, net of business acquisitions:

Accounts receivable
   (4,013 ) 5,916
Inventories
   (3,859 ) (9,460 )
Prepaid expenses and other current assets
   (7,316 ) 717
Accounts payable, accruals and other changes
   (280 ) 5,580


Net Cash Provided By Operating Activities
   46,576 45,188
Cash Flows Used In Investing Activities

Purchases of property, equipment and othernon-current intangible assets
   (16,297 ) (13,002 )
Proceeds from the sale of marketable securities
   211,327 102,957
Purchases of marketable securities
   (255,348 ) (115,117 )
Business acquisitions, net of cash acquired
   (468 ) (34,027 )


Net Cash Used In Investing Activities
   (60,786 ) (59,189 )
Cash Flows From Financing Activities

Exercise of stock options
   18,916 15,844
Excess income tax benefit from the exercise of stock options
   —   3,671


Net Cash Provided By Financing Activities
   18,916 19,515
Effect of Exchange Rates on Cash
   (207 ) (888 )


Net Increase In Cash and Cash Equivalents
   4,499 4,626
Cash And Cash Equivalents At Beginning Of Period
   77,567 55,257


Cash And Cash Equivalents At End Of Period
   $ 82,066 $ 59,883


	Three Months Ended
	August 31,
	2022			2021
Cash Flows (For) From Operating Activities
Net Income	$	5,209		$	17,077
Adjustments to reconcile net income to net cash ( f or) from operating activities:
Depreciation and amortization		5,729			5,682
Deferred income taxes		(1,439	)		(15	)
Share-based compensation		1,867			1,690
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable		4,819			4,036
Inventories		(8,330	)		(1,863	)
Prepaid expenses and other current assets		(14,682	)		(1,014	)
Accounts payable, accruals and other changes		(7,316	)		(2,383	)

Net Cash (For) From Operating Activities		(14,143	)		23,210

Cash Flows From (For) Investing Activities
Purchases of property, equipment and other non-current intangible assets		(12,996	)		(1,295	)
Proceeds from the sale of marketable securities		108,488			112,636
Purchases of marketable securities		(12,523	)		(136,748	)
Business acquisitions, net of cash acquired		(1,331	)		—

Net Cash From (For) Investing Activities		81,638			(25,407	)

Cash Flows From Financing Activities
Exercise of stock options and issuance of employee stock purchase plan shares		905			1,048

Net Cash From Financing Activities		905			1,048

Effect of Foreign Exchange Rates on Cash		(5,775	)		(3,170	)


Net Increase (Decrease) In Cash and Cash Equivalents		62,625			(4,319	)
Cash and Cash Equivalents, Beginning of Period		44,473			75,602

Cash and Cash Equivalents, End of Period	$	107,098		$	71,283

See notes to interim consolidated financial statements.

Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ACCOUNTING POLICIES

BASIS OF PRESENTATION

AND CONSOLIDATION

The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form

10-Q

and Article 10 of Regulation

S-X.

Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been ~~included.~~included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three ~~and nine~~ month ~~periods~~period ended ~~February 28, 2018~~August 31, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, ~~2018.~~2023. For more complete financial information, these consolidated financial statements should be read in conjunction with the ~~May 31, 2017~~ audited consolidated financial statements and the notes thereto included in ~~the Company’s~~our Annual Report on Form

10-K

for the fiscal year ended May 31, ~~2017.~~

2022.

Our functional currency is the U.S. dollar. We translate our

non-U.S.

operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our consolidated statement of income.

Share and per share amounts reflect the June 4, 2021

2-for-1

stock split as if it took place at the beginning of the periods presented.

Recent Accounting Pronouncements Not Yet Adopted

Reference Rate Reform

In March 2020, the FASB issued Update

2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in a new reference rate may be accounted for as a continuation of the existing contract. This guidance is effective upon issuance of the update and applies to contract modifications made through December 31, 2022. When we adopt this standard in the second quarter of fiscal 2023, we will use the Secured Overnight Financing Rate (SOFR). Adoption of this standard will not have a material impact on our consolidated financial statements and related disclosures.

Comprehensive Income (Loss)

Comprehensive income (loss) represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted

accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other

comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on our marketable securities.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

Table of Contents

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Leases

We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. Topic 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a

right-of-use

asset representing its right to use the underlying asset for the lease term.

Right-of-use

assets are recorded in other assets on our consolidated balance sheets. Current and

non-current

lease liabilities are recorded in other accruals within current liabilities and other

non-current

liabilities, respectively, on our consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. The

right-of-use

assets were $2,834,000 and $3,184,000 at August 31, 2022 and May 31, 2022, respectively. The total current and

non-current

lease liabilities were $2,899,000 and $3,228,000 at August 31, 2022 and May 31, 2022, respectively.

ESTIMATES AND ASSUMPTIONS

The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Accounts Receivable Allowance

Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts.

Inventory

The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants

not-to-compete

and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line basis; intangibles are generally amortized over 5 to 25 years.

Table of Contents

We review the carrying amounts of goodwill and other

non-amortizable

intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.

Long-Lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Business Combinations

We utilize the acquisition method of accounting for business combinations

. This method requires, among other things, that results of operations of acquired companies are included in Neogen’s results of operations beginning on the respective acquisition dates and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date; these are recorded in either other accruals within current liabilities (for expected payments in less than a year) or other

non-current

liabilities (for expected payments in greater than a year), both on our consolidated balance sheets. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other income (expense) in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed

months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.

Equity Compensation Plans

Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units.

To value equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can accommodate most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 7.

Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

Table of Contents

2. CASH AND MARKETABLE SECURITIES

Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were $107,098,000 and $44,473,000 at August 31, 2022 and May 31, 2022, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers at August 31, 2022. Changes in market value are monitored and recorded on a monthly basis; in the event of a downgrade in credit quality subsequent to purchase, the marketable securities investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable securities portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding current operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income.

Marketable Securities as of August 31, 2022 and May 31, 2022 are listed below by classification and remaining maturities.


(in thousands)	Maturity	August 31, 2022		May 31, 2022
Commercial Paper & Corporate Bonds	0 - 90 days	$	63,375	$	106,497
	91 - 180 days		60,950		61,373
	181 days - 1 year		57,135		91,706
	1 - 2 years		59,153		77,002

Total Marketable Securities		$	240,613	$	336,578

The components of marketable securities, consisting of commercial paper and corporate bonds, at August 31, 2022 are as follows:


(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds	$	244,125	$	—	$	(3,512	)	$	240,613

The components of marketable securities, consisting of commercial paper and corporate bonds, at May 31, 2022 are as follows:


(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds	$	339,540	$	7	$	(2,969	)	$	336,578

Table of Contents

3. INVENTORIES

Inventories are stated at the lower of cost, determined onby the

first-in,

first-out

method, or net realizable value. The components of inventories follow:

   February 28,
2018    May 31,
2017
   (in thousands)
Raw materials
   $ 35,774    $ 33,190
Work-in-process
   6,231    4,831
Finished and purchased goods
   35,501    35,123




   $ 77,506    $ 73,144


(in thousands)	August 31, 2022		May 31, 2022
Raw materials	$	62,134	$	58,667
Work-in-process		6,241		6,388
Finished and purchased goods		60,664		57,258

	$	129,039	$	122,313

4. REVENUE RECOGNITION

The Company determines the amount of revenue to be recognized through application of the following steps:

Identification of the contract with a customer;

Identification of the performance obligations in the contract;

Determination of the transaction price;

Allocation of the transaction price to the performance obligations in the contract; and

Recognition of revenue when, or as, the Company satisfies the performance obligations.

Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.

Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers, and the expected-value method for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.

The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.

The Company derives revenue from two primary sources - product revenue and service revenue.

Table of Contents

Product revenue consists of shipments of:

Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and

Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

Genomic identification and related interpretive bioinformatic services; and

Other commercial laboratory services.

Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.

Payment terms for products and services are generally 30 to 60 days.

The Company has no contract assets; contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are listed as Deferred revenue on the consolidated balance sheets.

The following table presents disaggregated revenue by major product and service categories for the three month periods ended August 31, 2022 and 2021:


	Three Months ended August 31,
(in thousands)	2022		2021
Food Safety
Natural Toxins, Allergens & Drug Residues	$	19,787	$	20,408
Bacterial & General Sanitation		10,728		11,165
Culture Media & Other		19,254		18,046
Rodent Control, Insect Control & Disinfectants		9,575		7,649
Genomics Services		5,299		5,454

	$	64,643	$	62,722

Animal Safety
Life Sciences	$	1,589	$	1,363
Veterinary Instruments & Disposables		14,673		15,337
Animal Care & Other		10,526		9,219
Rodent Control, Insect Control & Disinfectants		22,214		22,149
Genomics Services		18,704		17,515

	$	67,706	$	65,583

Total Revenues	$	132,349	$	128,305

Table of Contents

5. NET INCOME PER SHARE

The calculation of net income per share ~~attributable to Neogen Corporation~~ follows:

   Three Months Ended
February 28,    Nine Months Ended
February 28,
   2018    2017    2018    2017
   (in thousands, except per share amounts)
Numerator for basic and diluted net income per share:

Net income attributable to Neogen
   $ 16,586    $ 10,287    $ 45,600    $ 31,320
Denominator for basic net income per share:

Weighted average shares
   51,537    50,746    51,253    50,438
Effect of dilutive stock options
   700    633    761    723








Denominator for diluted net income per share
   52,237    51,379    52,014    51,161
Net income attributable to Neogen per share:

Basic
   $ 0.32    $ 0.20    $ 0.89    $ 0.62








Diluted
   $ 0.32    $ 0.20    $ 0.88    $ 0.61

~~The Board~~


	Three Months Ended
	August 31,
(in thousands, except per share amounts)	2022		2021
Numerator for basic and diluted net income per share:
Net income attributable to Neogen	$	5,209	$	17,077
Denominator for basic net income per share:
Weighted average shares		107,837		107,490
Effect of dilutive stock options and RSUs		20		619

Denominator for diluted net income per share	$	107,857	$	108,109
Net income attributable to Neogen per share:
Basic	$	0.05	$	0.16

Diluted	$	0.05	$	0.16

Table of ~~Directors declared a 4 for 3 stock split effective December 29, 2017. All share and per share amounts in this Form10-Q~~ ~~reflect amounts as if the split took place at the beginning of the periods presented.~~

4.Contents

6. SEGMENT INFORMATION

~~The Company has~~ AND GEOGRAPHIC DATA

We have two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, ~~cleaners,~~ disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

~~Neogen’s~~

Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s ~~Food Safety~~food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer ~~the Company’s~~our complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and ~~genomic~~genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.

The accounting policies of each of the segments are the same as those described in Note 1.

Segment information follows:

   Food
Safety    Animal
Safety    Corporate and
Eliminations
(1)    Total
   (in thousands)
As of and for the three months ended February 28, 2018


Product revenues to external customers
   $ 42,618    $ 35,524    $ —      $ 78,142
Service revenues to external customers
   5,027    12,723    —      17,750








Total revenues to external customers
   47,645    48,247    —      95,892
Operating income (loss)
   8,258    8,493    (838 )    15,913
Total assets
   188,075    215,371    192,155    595,601
As of and for the three months ended February 28, 2017


Product revenues to external customers
   $ 39,318    $ 34,646    $ —      $ 73,964
Service revenues to external customers
   3,631    10,790    —      14,421








Total revenues to external customers
   42,949    45,436    —      88,385
Operating income (loss)
   7,403    7,743    (795 )    14,351
Total assets
   183,419    215,243    108,636    507,298

   Food
Safety    Animal
Safety    Corporate and
Eliminations
(1)    Total
   (in thousands)
For the nine months ended February 28, 2018

Product revenues to external customers
   $ 129,621    $ 114,677    $ —      $ 244,298
Service revenues to external customers
   14,319    34,348    —      48,667








Total revenues to external customers
   143,940    149,025    —      292,965
Operating income (loss)
   25,704    27,691    (3,060 )    50,335
For the nine months ended February 28, 2017

Product revenues to external customers
   $ 112,592    $ 110,578    $ —      $ 223,170
Service revenues to external customers
   10,475    29,102    —      39,577








Total revenues to external customers
   123,067    139,680    —      262,747
Operating income (loss)
   24,286    24,616    (2,957 )    45,945


(in thousands)	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and for the three months ended August 31, 2022
Product revenues to external customers	$	57,790	$	49,002	$	—		$	106,792
Service revenues to external customers		6,853		18,704		—			25,557

Total revenues to external customers		64,643		67,706		—			132,349
Operating income (loss)		8,597		11,881		(14,416	)		6,062
Total assets		318,463		311,231		347,711			977,405

As of and for the three months ended August 31, 2021
Product revenues to external customers	$	55,945	$	48,068	$	—		$	104,013
Service revenues to external customers		6,777		17,515		—			24,292

Total revenues to external customers		62,722		65,583		—			128,305
Operating income (loss)		10,131		12,762		(1,148	)		21,745
Total assets		291,018		240,208		400,880			932,106

(1)	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

Table of Contents

The following table presents the Company’s revenue disaggregated by geographic location:


	Three months ended August 31,
(in thousands)	2022		2021
Domestic	$	80,642	$	77,779
International		51,707		50,526

Total revenue	$	132,349	$	128,305

7. EQUITY COMPENSATION PLANS

~~Qualified~~

Incentive and

non-qualified

options to purchase shares of common stock ~~may be~~have been granted to directors, officers and employees of ~~the~~

~~Company~~Neogen under the terms of the Company’s stock option plans. These options are granted at an exercise price of not less than the fair market value of the stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five or ten years. A summary of stock option activity during the ~~nine~~three months ended ~~February 28, 2018~~August 31, 2022 follows:

      Weighted-
      Average
   Shares    Exercise Price
   (in thousands)
Options outstanding June 1, 2017
   2,708    $ 32.88
Granted
   819    59.26
Exercised
   (668 )    28.23
Forfeited
   (144 )    37.31



Options outstanding February 28, 2018
   2,715    41.75


(Options in thousands)	Shares			Weighted- Average Exercise Price
Options outstanding June 1, 2022		3,244		$	32.13
Granted		—			—
Exercised		(4	)		10.75
Forfeited		(110	)		26.94

Options outstanding August 31, 2022		3,130		$	32.32

During the three ~~and nine~~ month periods ended ~~February 28, 2018~~August 31, 2022 and ~~2017,~~2021, the Company recorded ~~$1,026,000~~$1,867,000 and ~~$1,198,000 and $3,692,000 and $3,932,000,~~$1,690,000, respectively, of compensation expense related to its share-based awards. ~~On June 1, 2017, the Company adopted ASUNo. 2016-09,~~ which simplifies the accounting for share-based payments to employees. The guidance requires the recognition of the income effects of awards in the income statement when the awards vest or are settled, thus eliminating additional~~paid-in~~ capital pools. The guidance also allows for a policy election to account for forfeitures as they occur, rather than on an estimated basis, and requires that excess tax benefits be classified as an operating activity on the Statement of Cash Flows. The adoption of this ASU increased income tax expense by $331,000 for the three months ended February 28, 2018 as the reduction in the corporate tax rate from the tax reform enacted in December 2017 resulted in a partial reversal of tax benefit previously recorded at the higher corporate rate in the first and second quarters of the current fiscal year; year to date, income tax expense decreased by $3,463,000 as a result of adoption of the ASU.

The weighted-average fair value per share of stock options granted during fiscal ~~2018 and fiscal 2017,~~year 2022, estimated on the date of grant using the Black-Scholes option pricing model, was ~~$14.44 and $11.84, respectively.~~$8.49. The fair value of stock options granted was estimated using the following weighted-average ~~assumptions:~~

   FY 2018 FY 2017
Risk-free interest rate
   1.6% 1.2%
Expected dividend yield
   0.0% 0.0%
Expected stock price volatility
   27.7% 35.2%
Expected option life
   4.0 years 4.0 years

assumptions. No options were granted in the first quarter of fiscal year 2023.


	FY 2022
Risk-free interest rate		0.4	%
Expected dividend yield		0.0	%
Expected stock price volatility		32.8	%
Expected option life		3.12 years

The company grants restricted stock units (RSUs) to directors, officers and employees under the terms of the 2018 Omnibus Incentive Plan, which vest ratably over three and five year periods. The current units are expensed straight-line over the remaining weighted-average period of 3.8 years. On August 31, 2022 there was $6,442,000 in unamortized compensation cost related to

non-vested

RSUs. A summary of RSU activity during the three months ended August 31, 2022 follows:


(Options in thousands)	Shares			Weighted- Average Fair Value
RSUs outstanding June 1, 2022		257		$	36.14
Granted		—			—
Released		—			—
Forfeited		(4	)		37.60

RSUs outstanding August 31, 2022		253		$	36.12

Table of Contents

The Company ~~has an employee~~offers eligible employees the option to purchase common stock ~~purchase plan that provides for employee stock purchases~~ at a 5% discount to the lower of the market ~~price. The~~value of the stock at the beginning or end of each participation period under the terms of either the 2011 or the 2021 Employee Stock Purchase Plan; the discount is recorded in general and administrative ~~expense as~~expense. Total individual purchases in any year are limited to 10% of ~~the date of purchase.~~

~~6. NEW ACCOUNTING PRONOUNCEMENTS~~

~~In May 2014, the FASB issued ASU No.2014-09—Revenue~~ from Contracts with Customers (Topic 606). The new standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. In April 2016, the FASB issued Accounting Standards Update~~No. 2016-10—~~ ~~Revenue from Contracts with Customers (Topic 606), which amends and adds clarity to certain aspects of the guidance set forth in ASU2014-09~~ related to identifying performance obligations and licensing. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The guidance permits two methods of adoption: a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. The Company has formed an internal team to implement the new standard. This team has identified all revenue streams at each significant subsidiary and is currently reviewing contracts to evaluate the potential impact of adopting the new standard on the Company’s revenue recognition policies, procedures and control framework and ultimately on the Company’s consolidated financial statements and related disclosures. The Company will adopt this ASU on June 1, 2018 using the modified retrospective approach.

~~In February 2016, the FASB issued ASU No.2016-02—Leases~~ to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a~~right-of-use~~ asset representing its right to use the underlying asset for the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessor have not significantly changed from previous U.S. GAAP. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018; early adoption is permitted. Modified retrospective application is permitted with certain practical expedients. The Company expects to adopt this ASU on June 1, 2019 and is currently in the process of evaluating its lessee and lessor arrangements to determine the impact of this amendment on its consolidated financial condition and results of operations. This evaluation includes a review of revenue through leasing arrangements as well as lease expenses, which are primarily through operating lease arrangements at most of the Company’s facilities.

~~In March 2016, the FASB issued ASUNo. 2016-09~~ — Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting to provide guidance that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional~~paid-in~~ capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The Company adopted this standard effective June 1, 2017. Adoption of this ASU increased income tax expense by $331,000 for the three months ended February 28, 2018 as the reduction in the corporate tax rate from the tax reform enacted in December 2017 resulted in a partial reversal of tax benefit previously recorded at the higher corporate rate in the first and second quarters of the current fiscal year; year to date, income tax expense decreased by $3,463,000 as a result of adoption of the ASU.

~~In June 2016, the FASB issued ASU No.2016-13—Measurement~~ of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial instruments measured at amortized cost and certain other instruments, such as loans, receivables and held-~~to-maturity~~ debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost the Company expects to collect over the instrument’s contractual life. ASU~~2016-13~~ is effective for fiscal periods beginning after December 15, 2019 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company does not believe the adoption of this guidance will have an impact on its consolidated financial statements.

~~In August 2016, the FASB issued ASUNo. 2016-15—~~ ~~Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force). The amendments in ASU2016-15~~ address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under FASB Accounting Standards Codification (FASB ASC) 230, Statement of Cash Flows. The amendments in ASU~~2016-15~~ are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet adopted this update and is currently evaluating the impact of ASU~~No. 2016-15~~ ~~on its consolidated financial statements.~~

7.compensation.

8. BUSINESS ~~AND PRODUCT LINE ACQUISITIONS~~

COMBINATIONS

The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

On ~~December 1, 2016,~~September 17, 2021, the Company acquired the stock of ~~Quat-Chem Ltd.~~CAPInnoVet, Inc., a ~~chemical company~~companion animal health business that ~~manufactures biosecurity products, based~~provides pet medications to the veterinary market. This acquisition provides entry into the retail parasiticide market and enhances the Company’s presence in ~~Rochdale, England.~~companion animal markets. Consideration for the purchase was ~~$21,606,000~~net cash of $17.9 million paid at closing, including $150,000 of cash placed in ~~cash and~~escrow payable to the former owners in twelve months. There is also the potential for performance milestone payments to the former owners of up to ~~$3,778,000~~$6.5 million and the Company could incur up to $14.5 million in future royalty payments. The final purchase allocation, based upon the fair value of ~~contingent~~these assets and liabilities determined using the income approach, included accounts receivable of $308,000, inventory of $531,000, prepayments of $296,000, accounts payable of $120,000, other current liabilities of $84,000,

non-current

liabilities of $6.5 million (contingent consideration ~~due at the end~~accrual calculated using a Monte Carlo simulation utilizing inputs such as probability and timing of ~~each~~milestone achievements, revenue forecasts and volatility, and estimated discount rates relating to established future cash flows of the ~~first two years, based~~business), intangible assets of $19.2 million (with an estimated life of

15-20

years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The $150,000 placed in escrow was paid to the former owners on ~~an excess~~September 21, 2022. The business is operated from our location in Lexington, KY, reporting within the Animal Safety segment.

On November 30, 2021, the Company acquired the stock of Delf (U.K.) Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products, and Abbott Analytical Ltd., a related service provider. This acquisition will expand the Company’s line of dairy hygiene products and will enhance our cleaner and disinfectant product portfolio. Consideration for the purchase was net ~~sales formula.~~cash of $9.5 million paid at closing, including $722,000 of cash placed in escrow payable to the former owner in one year. The ~~final~~preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of ~~$4,684,000,~~$1,059,000, inventory of ~~$1,243,000, land,~~$972,000, net property, plant and equipment of ~~$2,526,000,~~$152,000, prepayments of $31,000, accounts payable of ~~$2,197,000, deferred tax liability of $1,133,000, contingent consideration accrual of $1,058,000,~~$497,000, other current liabilities of ~~$604,000,non-amortizable~~$378,000,

non-current

deferred tax liabilities of $780,000, intangible assets of ~~$1,889,000, intangible assets of $6,900,000~~$3.1 million (with an estimated life of~~5-15~~

10-15

years) and the remainder to goodwill

(non-deductible

for tax purposes). These values are Level 3 fair value measurements. In January 2018, the Company paid the former owners $249,000 in contingent consideration based on the achievement of sales targets in the first year, and recorded a credit of $255,000 to other income, reducing the contingent consideration accrual by a corresponding amount; $554,000 remains accrued for contingent consideration payable at the end of the second year. This business continuesThe companies continue to operate ~~in its~~from their current location ~~and is managed by Neogen Europe,~~in Liverpool, England, reporting within the Food Safety ~~segment.~~

segment and are managed through Neogen’s Scotland operation.

On December ~~27, 2016,~~9, 2021, the Company acquired the stock of ~~Rogama Industria e Comercio, Ltda.~~Genetic Veterinary Sciences, Inc., a ~~company that develops~~companion animal genetic testing business providing genetic information for dogs, cats and ~~manufactures rodenticides~~birds to animal owners, breeders and ~~insecticides, based near Sao Paulo, Brazil.~~veterinarians. This acquisition will further expand the Company’s presence in the companion animal market. Consideration for the purchase was ~~$12,428,000~~$11.4 million in ~~cash and up to $2,069,000 of contingent consideration, due at the end of each of the first two years, based on an excess~~ net ~~sales formula.~~cash. The ~~final~~preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of ~~$1,866,000, othernon-current~~ ~~assets of $26,000,~~$38,000, net inventory of ~~$960,000, land,~~$292,000, net property, plant and equipment of ~~$4,734,000,~~$399,000, prepayments of $54,000, accounts payable of $325,000, unearned revenue of $1.9 million, other current liabilities of ~~$2,562,000, contingent consideration accrual of $213,000,non-current~~ ~~deferred tax liability of $1,307,000,non-amortizable~~$321,000, intangible assets of ~~$870,000, intangible assets of $5,112,000~~$5.5 million (with an estimated life of

5-15

years) and the remainder to goodwill~~(non-deductible~~ for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and is managed by Neogen do Brasil, reporting within the Food Safety segment.

On September 1, 2017, the Company acquired the assets of The University of Queensland Animal Genetics Laboratory, an animal genomics laboratory located near Brisbane, Australia. This acquisition is intended to accelerate the growth of the Company’s animal genomics business in Australia and New Zealand. Consideration for the purchase was $2,063,000; $468,000 has been paid in cash with the remainder due in annual installments over the next five years. The preliminary purchase price allocation included inventory of $19,000, equipment of $419,000,~~non-current~~ ~~liabilities of $1,629,000, intangible assets of $850,000 (with an estimated life of5-15~~ ~~years) and the remainder to goodwill(non-deductible~~ (deductible for tax purposes). These values are Level 3 fair value measurements. The ~~new~~ business ~~renamed Neogen Australasia, continues to operate in~~is operated from its current location in Spokane, Washington, reporting within the Animal Safety segment.

Table of Contents

On July 1, 2022, Neogen acquired all of the stock of

Thai-Neo

Biotech Co., Ltd., a longstanding distributor of Neogen’s food safety products to Thailand and Southeast Asia. This acquisition gives Neogen a direct sales presence in Thailand. Consideration for the purchase was $1,558,000 in net cash, with $1,311,000 paid at closing and $234,000 payable on October 1, 2023. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $179,000, inventory of $232,000, net property, plant and equipment of $16,000, other

non-current

assets of $6,000, accounts payable of $3,000,

non-current deferred

tax

liabilities of $120,000,

intangible assets of $

600,000

(with an estimated life of

5-15

years) and the remainder to goodwill

(non-deductible

for tax purposes). The business continues to operate in Bangkok, Thailand, reporting within the Food Safety segment.

For each completed acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed.

3M Food Safety transaction

On September 1, 2022, after the close of the first quarter, Neogen, 3M, and Garden SpinCo, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business, closed on the transaction which had previously been announced in December 2021, combining 3M’s Food Safety business with Neogen in a Reverse Morris Trust transaction. Immediately following the transaction, Garden SpinCo stockholders own, in the aggregate, approximatel

y 50.1% of the issued and outstanding shares of Neogen common stock and

pre-merger

Neogen shareholders own, in the aggregate, approximately 49.9%

of the issued and outstanding shares of Neogen common stock. Garden SpinCo became a subsidiary of Neogen on September 1. On closing, the transaction valued the 3M’s Food Safety business at approximate

ly $3.3

billion based on the issuance of 108,269,946 shares of Neogen common stock at a price of

$20.90

per share on August 31, 2022 and

billion in debt assumed by Neogen post close. 3M’s Food Safety business funded 3M consideration valued at approximat

ely $1 billion at

close.

3M’s former Food Safety business is a leading provider of food safety testing solutions. It offers a broad range of food safety testing solutions that support multiple industries within food and beverage, helping producers to prevent and protect consumers from foodborne illnesses. The business has a broad global presence with products used in more than 60 countries and a diversified revenue base of more than 100,000 end-user customers. The combination of Neogen and 3M’s Food Safety business creates a leading innovator with an enhanced geographic footprint, innovative product offerings, digitization capabilities, and financial flexibility to capitalize on robust growth trends in sustainability, food safety, and supply chain integrity.

This transaction is a business combination and will be accounted for using the acquisition method. The purchase price of 3M’s Food Safety business will be allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair value at the acquisition date. Any excess of the purchase price over the fair value of the net identified assets acquired and liabilities assumed will be recorded as goodwill. Transaction costs related to the transaction will be expensed as incurred. We are currently preparing the valuations and other procedures necessary to determine the purchase price allocation and will record our initial fair value estimates and the results of operations of the acquired business from the acquisition date forward in our condensed consolidated financial statement for the second quarter of fiscal 2023.

9. LONG TERM DEBT

~~The~~

At August 31, 2022, the Company ~~has~~had a financing agreement with a bank providing for ana $15,000,000 unsecured revolving line of credit, ~~of $15,000,000,~~ which ~~expires~~

originally

expire

on ~~September~~November 30, ~~2019.~~2023. There were no advances against the line of credit during fiscal ~~year 2017~~2022 and there ~~have been none thus far in fiscal year 2018; there was~~were no ~~balance outstanding at February 28, 2018.~~advances through August 31, 2022. Interest on any borrowings ~~remained~~was at LIBOR plus 100 basis points (rate under the terms of the agreement was ~~2.82%~~3.55% at ~~February 28, 2018)~~August 31, 2022). Financial covenants ~~include~~included maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at ~~February 28, 2018.~~

9.August 31, 2022. This facility was replaced by the five-year secured term loan facility and five-year

secured

revolving facility described below.

On June 30, 2022, Garden Spin

o entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650.0 million and a five-year senior secured revolving facility in the amount of $150.0 million (collectively, the “Credit Facilities”), which became available in connection with the merger and related transactions. The loan facility was funded to Garden Spinco on August 31, 2022, and upon the effectiveness of the merger on September 1, 2022, became Neogen’s obligation. Financial covenants include maintaining specified levels of funded debt to EBITDA, and debt service coverage. Pricing for the loan is term SOFR plus 235 basis points. The Credit Facilities, together with the Notes below, when incurred, represent the financing incurred in connection with the merger

of the 3M Food Safety business with Neogen.

In July 2022, Garden SpinCo closed on an offering of $350.0 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par.

The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Garden SpinCo did not receive any proceeds from the sale of the Notes by the selling securityholder. Prior to the distribution of the shares of Garden SpinCo’s common stock to 3M stockholders, the Notes were guaranteed on a senior unsecured basis by 3M. Upon consummation of such distribution, 3M was released from all obligations under its guarantee. Upon the effectiveness of the merger on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.

Table of Contents

10. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company ~~expenses~~currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these annual costs of remediation, which have ranged from $38,000 to ~~$57,000~~$131,000 per year over the past five years. The Company’s estimated remaining liability for these costs was $916,000 at ~~February 28, 2018~~both August 31, 2022 and May 31, ~~2017,~~2022, measured on an undiscounted basis over an estimated period of 15 ~~years; $54,000~~years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources (WDNR) and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. However, the Company has agreed to a pilot study in which chemical reagents are injected into the ground in an attempt to reduce

on-site

contamination and is currently working with its consultant to design the system. At this time, the outcome of the pilot study is unknown, but a change in the current remediation strategy, depending on the alternative selected, could result in an increase in future costs and ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded $100,000 as a current liability, and the remaining $816,000 is recorded ~~within current liabilities and the remainder is recorded within~~in other

non-current

liabilities in the consolidated balance ~~sheet.~~

sheets.

On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities.

In addition to responding to the administrative subpoena, the Company has implemented additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures will further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to U.S. economic sanctions and export control laws. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a material impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to expense and recorded a reserve of $600,000 to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for this issue. The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

~~10. STOCK PURCHASE~~

11. DERIVATIVES

We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions.

Derivatives Not Designated as Hedging Instruments

We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and we enter into approximately 11 foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our consolidated balance sheets, classified as Level 2 in the fair value hierarchy; gains and losses from these contracts were recognized in other income in our consolidated statements of income. The ~~Company has a stock repurchase program, authorized by the Board~~notional amount of ~~Directors~~forward contracts in ~~calendar year 2008, to purchase, subject to market conditions, up to 1,500,000 shares~~place was $18,221,000 and $4,424,000 as of ~~the Company’s common stock. As~~August 31, 2022 and May 31, 2022, respectively.

Table of ~~February 28, 2018, 1,350,632 shares~~Contents


(In thousands)
Fair Value of Derivatives Not Designated as Hedging Instruments	Balance Sheet Location	August 31, 2022		May 31, 2022
Foreign currency forward contracts, net	Prepaid and Other	$	421	$	(78	)

The location and amount of gains from derivatives not designated as hedging instruments in our consolidated statements of income were ~~available to be repurchased under the program. There were no purchases in fiscal year 2017 and there have been none thus far in fiscal year 2018.~~

as follows:


(In thousands)
Derivatives Not Designated as Hedging Instruments	Location in statements of income	August 31, 2022		August 31, 2021
Foreign currency forward contracts	Other income (expense)	$	882	$	521

Table of Contents

PART I – FINANCIAL INFORMATION

~~Item 2.~~

~~Management’s Discussion and Analysis of Financial Condition and Results of Operations~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form

10-Q.

For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be ~~forward looking~~forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing

COVID-19

pandemic on our business, global business disruption caused by the Russia invasion in Ukraine and related sanctions, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form

10-Q

was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

~~Critical Accounting Policies~~

TRENDS AND UNCERTAINTIES

During fiscal 2022 and ~~Estimates~~

~~The discussion~~the first quarter of fiscal 2023, we have experienced higher than expected input cost inflation, including higher transportation, supply chain and ~~analysis~~labor costs, that negatively impacted operating results. Pricing actions taken during fiscal 2022 and the first quarter of fiscal 2023 mitigated some, but not all, of the ~~Company’s~~inflationary pressures. Ongoing inflation may also have an impact on our customer’s purchasing decisions and order patterns. We estimate inflation will continue to affect us in the remainder of fiscal 2023, although at this time it is impracticable to quantify the impact.

Although we have no operations in or direct exposure to Russia, Belarus and Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict on the global economy. To date, our European operations and customer base have not been materially impacted by the conflict, however, as the conflict continues or worsens, it may impact our business, financial condition or results of operations in the remainder of fiscal 2023.

As we continue to monitor the ongoing

COVID-19

pandemic, our top priority remains protecting the health and safety of our employees, their families, and those in our communities. Safety guidelines and procedures have been developed for

on-site

employees and these policies are regularly monitored and updated by our internal Emergency Response Team.

COVID-19

continues to impact our business operations and financial results. A number of our product lines have been negatively impacted due to decreased demand in our customers’ businesses around the world. Many of our markets are recovering, but the pandemic has continued to adversely impact our customers and ultimately, our revenues. We have also experienced supply chain difficulties including vendor disruptions, border closures, shipping issues and significantly increased shipping costs; labor shortages and higher labor costs, as we have had to use staffing agencies and increase our base pay in a number of areas of the Company to fill open positions and to cover for COVID-related absences, and restricted travel, which hinders our ability to connect with customers.

Overall, the impact of

COVID-19

remains uncertain and ultimately depends on the length and severity of the pandemic, inclusive of the introduction of new strains of the virus; government actions taken in response; vaccination rates and effectiveness; the impact of vaccination requirements; extent of protection provided by prior viral infection; and the macroeconomic environment. We will continue to evaluate the nature and extent to which

COVID-19

has impacted our business, supply chain, including labor availability and attrition, consolidated results of operations, financial condition, and ~~results~~liquidity; we expect it to continue to impact us through at least the end of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, those related to receivable allowances, inventories, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

~~There were no significant changes to the contractual obligations or contingent liabilities and commitments disclosed in the Company’s Annual Report on Form10-K~~ ~~for the fiscal year ended May 31, 2017.~~

~~The Company adopted ASUNo. 2016-09~~ ~~related to share-based compensation on June 1, 2017. (See Note 5 Equity Compensation Plans for further discussion).~~

On December 22, 2017, the Tax Cuts and Jobs Act, (“the Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The Company will compute its income tax for theour fiscal year ending May 31, ~~2018 using a blended Federal Tax Rate~~2023.

Table of ~~29.2%.~~

~~In December 2017,~~Contents

International sales rose 2% in the first quarter of fiscal year 2017. Earnings per share for the third quarter of fiscal 2018 were $0.32 compared to $0.20 per share in the same period a year ago. Net earnings for the third quarter were favorably impacted by adjustments resulting from tax reform legislation enacted in December 2017. For the first nine months of the current fiscal year, net income attributable to Neogen increased 46% to $45.6 million, or $0.88 per fully diluted share, compared to $31.3 million, or $0.61, for the same period in the prior fiscal year. For the year to date period, net earnings were favorably impacted by tax reform, excess tax benefits from stock option exercises, and the favorable conclusion of an IRS audit.

~~Food Safety segment revenues increased 11% and Animal Safety segment revenues increased 6% for the three month period ended February 28, 2018, each~~2023 compared to the same period in the prior year. ~~For~~Currency translations decreased comparative revenues by approximately $3.9 million in the first quarter of fiscal 2023, due to the ~~overall organic~~stronger U.S. dollar relative to currencies in the United Kingdom, Europe, Australia, and Argentina for the comparative period. On a neutral currency basis, international sales increased 10%. Excluding revenues from the Delf/Abbott Analytical and

Thai-Neo

Biotech acquisitions, the increase was 7%~~; organic growth~~ on a neutral currency basis. Revenue changes, expressed in percentages, for the three month period of fiscal 2023 compared to the same period in the ~~Food Safety and Animal Safety segments was 9% and~~prior year are as follows for each of our international locations:


	Three Months Ended August 31, 2022
	Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency
U.K. Operations (including Neogen Italia)		5	%		19	%
Megazyme		(13	)%		1	%
Brazil Operations		13	%		14	%
Neogen Latinoamerica		19	%		20	%
Neogen Argentina		34	%		78	%
Neogen Uruguay		1	%		(6	)%
Neogen Chile		(4	)%		16	%
Neogen China		(18	)%		(14	)%
Neogen India		25	%		33	%
Neogen Canada		(7	)%		(3	)%
Neogen Australasia		(8	)%		(2	)%

Combined revenues at our U.K. operations increased 5%~~, respectively. The acquisitions of Rogama, purchased inmid-December~~ ~~2016, and Neogen Australasia, in September 2017, contributed $1.6 million to the overall revenue growth~~ in the ~~third quarter. Food Safety segment revenues~~first quarter, led by a 31% increase in sales of cleaners and disinfectants, aided by the acquisition of Delf (UK) Ltd. in December 2021; in local currency, the organic increase was 12%. For the Megazyme operation, located in Ireland, the prior year first quarter included end sales to customers in the U.S. These end customer sales were transitioned to our U.S. operations in August 2021.

Sales in Brazil increased ~~17%~~13% in this year’s first quarter, driven by strong sales of the company’s mycotoxin test kits, including tests to detect aflatoxin and ~~Animal Safety segment revenues increased 7%~~deoxynivalenol (DON), as well as increases in veterinary instruments, insect and rodent controls products, and genomics testing. Neogen Latinoamerica sales rose 19% for the ~~year to date period. Overall organic~~first quarter, led by increases across the company’s diagnostic testing portfolio and culture media, as well as higher sales ~~increased 7%~~of rodent control products and cleaners and disinfectants. Sales at Neogen China decreased 18% for the three month period as the country’s

COVID-19

related lockdowns continued to negatively impact sales in the first quarter of the fiscal year. Revenues at Neogen’s Australasia operations decreased 8% as a large

non-recurring

culture media order in the prior year ~~to date period; the organic increases were 9% for the Food Safety segment~~was only partially offset by bovine genomic service increases.

Service revenue, which includes genomics testing and 6% for the Animal Safety segment. The previously discussed acquisitions, and Quat-Chem, purchased on December 1, 2016, contributed $11.1 million to the overall sales increase for the nine month period.

~~International sales were $37.4~~other laboratory services, was $25.6 million in the ~~third~~first quarter of fiscal ~~2018,~~2023, an increase of ~~17%~~5% over the prior year first quarter revenues of $24.3 million. Excluding the contribution from the December 2021 acquisition of Genetic Veterinary Sciences and negative currency impact, service revenue increased 2%. Growth in the beef markets in the U.S. and Brazil was partially offset by COVID-related shutdowns in China and a difficult comparison due to a large domestic research project recorded in the prior year.

Food Safety

Natural Toxins, Allergens

& Drug Residues –

Sales in this category decreased 3% for the three month period ended August 31, 2022, compared to the same period in the prior year. ~~Expressed as~~In the first quarter, aflatoxin test kit revenues increased 25% primarily from an aflatoxin outbreak in Brazil and new business earned in Mexico and Central America. This increase was offset by a ~~percentage of sales, international sales were 39.0%~~9% decline across the company’s allergen testing portfolio caused by softening market conditions and supply disruptions for certain products.

Bacterial

& General Sanitation –

Revenues in the quarter, compared to 36.3% in the third quarter a year ago. For the year to date, international sales were $110.5 million, an increase of 20%; international sales were 37.7% of total sales in the current year to date period and 35.1% in the prior year. For each comparative period, international revenue increases were the result of the acquisitions of Quat-Chem (England), Rogama (Brazil) and Neogen Australasia (Australia), and to a lesser extent, revenue increases at existing Company locations. Currency translation had a positive effect on international revenues of approximately $1.9 million in the third quarter of fiscal 2018 as the pound, euro, and peso were stronger on average against the dollar than the same period a year ago;this category decreased 4% for the ~~year to date period, the positive revenue impact was $2.5 million.~~

~~Revenues at Neogen Europe increased 16% in U.S. dollars in the third~~first quarter compared to the same period in the prior ~~year; for~~year. In the ~~nine month period,~~first quarter this year, there was a significant decrease in Soleris

equipment sales ~~rose 10%. For~~due to a difficult comparison to strong prior year placements. Soleris

consumables recorded a 6% increase over the ~~quarter, a 39% increase in genomics revenues offset lower mycotoxin~~prior year, and the ANSR pathogen detection product line grew 13% from new equipment placements and higher test kit ~~sales, as last year’s deoxynivalenol (DON) outbreak~~sales.

Culture Media

& Other –

Sales in ~~corn crops in western Europe did not repeat in the current year. For the year to date period, genomics sales~~this category increased 34% and helped to offset lower DON test kit sales. Sales at Lab M, the Company’s subsidiary in England, increased 20% in the third quarter and 25% for the nine month period, as its culture media products continued to be integrated into Neogen’s global sales and marketing channels. Neogen Latinoamerica recorded a sales increase of 19% in the third quarter; Food Safety products increased 21% and Animal Safety products increased 17%, with broad-based gains recorded in both categories. For the year to date, revenues rose 18%, with Food Safety products and increases in genomics services providing the majority of the increase. Revenues at Neogen do Brasil declined 2% in the year’s third quarter, as a decrease in forensic test kit sales resulting from increased competition and customer losses caused by conversion to different testing methods more than offset increased sales of mycotoxin and dairy drug residue test kits. For the year to date, revenues increased 18%. Neogen China sales increased 28% in the third quarter and 21% for the year to date period, each compared to the same periods in the prior year; for each period, increases were driven by strength in genomics services and animal safety products. Revenues for Neogen India declined 37% for the quarter, as a large cleaner and disinfectant order in the prior year’s third quarter did not repeat; for the year to date, revenues were flat, as higher sales of Food Safety products and testing services were almost entirely offset by the cleaner and disinfectant revenue from last year’s third quarter which did not repeat this year.

~~Service revenue was $17.8 million~~7% in the quarter ended ~~February 28, 2018, an increase of $3.4 million, or 24%,~~August 31, 2022 compared to ~~$14.4 million in~~ the ~~third~~first quarter ~~of the prior year. For the year to date period, service revenue was $48.7 million, an increase of $9.1 million, or 23%, compared to $39.6 million~~ in the prior year. The growth, for both the quarter and year to date periods, was led by increases in sales to the global cattle and companion animal markets, increased testing volumes with a large poultry customer and, to a lesser extent, revenues from the acquisition of Neogen Australasia, in September 2017.

~~Revenues~~

   Three Months ended February 28,
         Increase/
   2018    2017    (Decrease)    %
      (in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues
   $ 16,807    $ 16,453    $ 354    2 %
Bacterial & General Sanitation
   8,992    8,348    644    8 %
Dehydrated Culture Media & Other
   10,511    10,383    128    1 %
Rodenticides, Insecticides & Disinfectants
   7,359    5,040    2,319    46 %
Genomics Services
   3,976    2,725    1,251    46 %







   $ 47,645    $ 42,949    $ 4,696    11 %
Animal Safety
Life Sciences
   $ 2,769    $ 2,332    $ 437    19 %
Veterinary Instruments & Disposables
   10,630    10,000    630    6 %
Animal Care & Other
   7,535    6,311    1,224    19 %
Rodenticides, Insecticides & Disinfectants
   14,590    16,111    (1,521 )    (9 )%
Genomics Services
   12,723    10,682    2,041    19 %







   $ 48,247    $ 45,436    $ 2,811    6 %







Total Revenues
   $ 95,892    $ 88,385    $ 7,507    8 %







   Nine Months ended February 28,
         Increase/
   2018    2017    (Decrease)    %
      (in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues
   $ 54,960    $ 53,090    $ 1,870    4 %
Bacterial & General Sanitation
   27,435    25,340    2,095    8 %
Dehydrated Culture Media & Other
   32,483    29,792    2,691    9 %
Rodenticides, Insecticides & Disinfectants
   18,175    7,088    11,087    156 %
Genomics Services
   10,887    7,757    3,130    40 %







   $ 143,940    $ 123,067    $ 20,873    17 %
Animal Safety
Life Sciences
   $ 7,589    $ 7,261    $ 328    5 %
Veterinary Instruments & Disposables
   32,804    29,281    3,523    12 %
Animal Care & Other
   24,056    21,563    2,493    12 %
Rodenticides, Insecticides & Disinfectants
   50,228    52,796    (2,568 )    (5 )%
Genomics Services
   34,348    28,779    5,569    19 %







   $ 149,025    $ 139,680    $ 9,345    7 %







Total Revenues
   $ 292,965    $ 262,747    $ 30,218    12 %

The Company’s Food Safety segment revenues were $47.6 million in the quarter ended February 28, 2018, an increase of 11% compared to the same period in the prior year. For the nine month period, Food Safety revenues increased 17% to $143.9 million. Organic growth for the segment was 9% for both the quarter and year to date periods, with the acquisition of Rogama, occurring on December 21, 2016, contributing the remainder of the growth.

~~Natural Toxins, Allergens & Drug Residues sales increased 2% in the third quarter; revenues for the year to date period increased 4%.~~ Sales of ~~dairy drug residue kits, used to detect the presence of antibiotics in raw milk,~~food quality and nutritional analysis products increased 29% in the third quarter as new products continued to gain share, particularly in international markets; for the year to date period, dairy drug residue test kit revenues rose 15%. Allergen test kit sales increased 14% and 13% in the three and nine month periods ended February 28, 2018, respectively, as product recalls relating to allergenic contamination of food continued to expand the market. Sales of test kits to detect the presence of natural toxins in grain crops decreased 17% in the third quarter. An 11% increase in aflatoxin test kit sales, due to moderate

~~outbreaks in U.S. and Brazilian corn crops, was offset~~ by a 41% decrease in sales of deoxynivalenol (DON) test kits, as prior year outbreaks of DON in corn crops in the U.S., Canada and Europe did not recur in the current year. For the year to date period, sales of natural toxin test kits decreased 7%.

Bacterial & General Sanitation sales increased 8% in both the three and nine month periods ended February 28, 2018. Within this category, the Company’s AccuPoint sanitation monitoring product line increased 18% in the third quarter and 19% for the year to date period, on sales strength in both reader equipment and consumable supplies. Sales of test kits to detect pathogens increased 22% in the third quarter, led by strength in~~Listeria~~ ~~products, including the Company’s new~~~~Listeria~~ Right Now test kit that launched earlier in the fiscal year. The Company also benefitted from strong sales of equipment used with the Company’s ANSR line of test kits to detect various pathogens, as the Company gained new customers; overall pathogen revenues increased 14% for the year to date period. Revenues for the Company’s consumable product lines to detect spoilage organisms in processed foods decreased 2% in the current quarter but increased 3% for the nine month period.

Dehydrated Culture Media & Other sales increased 1% in the third quarter. This category includes forensic test kits sold through the Company’s Brazilian subsidiary. Demand for these kits from customers located in Brazil had increased dramatically in9% over the prior year, ~~due~~as the products were integrated into U.S. channels. The recently introduced Neogen Analytics platform continued to ~~a new requirement for drug testing of commercial truck drivers, however, sales of these kits in Brazil have decreased~~make strong inroads in the current year as a result of increased competition and customer losses caused by conversion to different testing methods. In the third quarter, the Company’s worldwide Lab M sales increased 21% and Acumedia sales increased 6%.

~~Sales of Rodenticides, Insecticides~~market.

Rodent Control, Insect Control

& Disinfectants ~~products sold through the Company’s Food Safety operations increased 46% in the third quarter; the organic sales increase~~–

Revenues in this category ~~was 29%. For the nine month period, sales~~ increased $11.1 million; excluding first year sales of the Quat-Chem and Rogama acquisitions, the year to date sales increase was 16%. In the third quarter, the increase was primarily due to Rogama shipping a large order resulting from a government contract; this sale is unlikely to recur25% in the ~~next 12 months. The increase in sales was partially offset by termination~~first quarter of ~~a distribution agreement in January 2017, which resulted in a decline in sales for those distributed products of $143,000 in the third quarter and $859,000 for the year~~fiscal 2023 compared to ~~date.~~

~~Genomics Services revenue recorded in the Food Safety segment increased 46% and 40% for the three and nine month periods, respectively, due primarily to growth of these services in Europe.~~

~~Sales for the Company’s Animal Safety segment were $48.2 million in the third quarter, an increase of 6% over~~ the same period a year ago. ~~Revenues for~~Excluding the ~~nine month period increased 7% to $149 million compared to $139.7 million in~~revenue contribution from the ~~prior year. Organic growth~~Delf acquisition in this ~~segment~~category, the overall increase was 5% and 6% in the three and nine month periods, respectively; the Neogen Australasia acquisition in September 2017 contributed the remainder of the growth. Sales of Life Sciences products increased 19% in the third quarter, partially9%, primarily due to ~~order timing, and have risen 5% for the year to date period. The Company has increased volumes of forensic test kits sold to commercial labs in the U.S.~~

Veterinary Instruments & Disposables revenues increased 6% and 12% for the three and nine month periods, respectively. For both periods, the increase is primarily the result of strength in detectable needles, syringes and animal marking products. Sales of Animal Care & Other products increased 19% in the quarter ended February 28, 2018, compared to the same period in the prior year; the year to date increase was 12%. The increase in the current year is due to market share gains of supplements for companion animals and vitamin injectables, and increased sales of vaccines to a large distributor; additionally, last year’s results included sales credits totaling $1.1 million in the first quarter as the Company removed its canine thyroid product from its distribution channels, after the FDA approved a new drug application for a competitive product.

~~Rodenticides, Insecticides & Disinfectants sales decreased 9% in the quarter and 5% for the year to date period, as the termination of a distribution agreement with a manufacturer~~higher demand of cleaners and disinfectants in ~~January 2017 resulted~~Europe, Brazil, Mexico and Central America.

Genomics Services –

Sales of genomics services sold through our international Food Safety operations decreased 3% for the three month period ended August 31, 2022. Increased beef business in ~~lost sales for those distributed products of $1.4 million~~Brazil was more than offset by unfavorable currency comparisons in the ~~third quarter of the current fiscal year~~U.K. and ~~$3.9 million for the year to date period. These losses were offset by an 11% increase~~COVID-related lab closures in ~~rodenticide sales~~China.

Animal Safety

Life Sciences –

Sales in this category increased 17% in the ~~third~~first quarter, ~~as the Company gained incremental business with several large customers; year to date sales rose by 9%.~~

~~Genomics Services increased 19% in both the third quarter and year to date periods, respectively, each~~ compared to the same period in the prior year. The ~~growth~~increase was due to higher demand from customers purchasing substrates and reagents used in clinical diagnostic test kits.

Veterinary Instruments

& Disposables –

Revenues in this category decreased 4% for ~~both periods was led~~the three month period ended August 31, 2022, primarily due to a 6% decrease in sales of veterinary instruments. This category had increased by a strong 52% in the first quarter a year ago.

Animal Care

& Other –

Sales of these products increased 14% in the three month period ended August 31, 2022; excluding the contribution of parasiticides from the September acquisition of CAPInnoVet, revenues in this category increased 9%. Sales of other animal care products, including supplements and vitamin injectables, increased 16% on continued strong end customer demand.

Rodent Control, Insect Control

& Disinfectants –

Revenues were flat for the three month period ended August 31, 2022, as compared to the same period in the prior year. Sales of insect control products rose 14% in the quarter and cleaners and disinfectants sales increased 7%. These increases were offset by a 12% decrease in rodenticide sales, the result of diminished rodent pressure in the U.S.

Genomics Services –

Sales in this category increased 7% in the first quarter compared to the prior year; excluding the contribution from Genetic Veterinary Sciences, revenues declined 3%. Domestic increases in ~~sales to~~ the ~~global cattle and companion animal markets, higher~~beef market were more than offset by unfavorable currency comparisons in Australia, lower sample volumes from a large ~~poultry~~ customer in the porcine market and a difficult prior year comparison due to a ~~lesser extent, revenues from the acquisition of Neogen Australasia, in September 2017.~~

large research project which did not recur.

Gross Margin

Gross margin, expressed as a percentage of sales, was ~~47.5%~~47.0% in the ~~third~~first quarter of fiscal ~~2018~~2023 compared to ~~46.3%~~46.8% in the same quarter a year ago. ~~Gross~~Animal Safety gross margins increased 200 basis points, with pricing actions taken in the prior fiscal year and a mix shift towards higher margin animal care products driving the improvement. Food Safety gross margins declined 160 basis points, primarily from the impact of lower gross margins from the Delf acquisition. Within each segment, increased raw material and freight in costs continued to pressure gross margins in certain product lines.

Operating Expenses

Operating expenses were $56.2 million in the first quarter of fiscal 2023, compared to $38.3 million in the same quarter of the prior year. Legal, consulting and other professional fees and expenses totaling $13.7 million were incurred in the first quarter of the current fiscal year related to our combination with 3M’s Food Safety business, which closed on September 1, 2022. Excluding costs related to the transaction, run rate operating expenses for the first quarter were $42.5 million, an increase of 11% compared to the prior year. Operating expenses for businesses acquired in the past year totaled $2.1 million and represented 50% of the increase for the first quarter of fiscal 2023.

Sales and marketing expenses were $23.4 million in the first quarter of fiscal 2023, compared to $20.6 million in last year’s first quarter, an increase of 14%. The increase in expense was driven by higher personnel related spending, the result of headcount additions and compensation increases. In addition, travel, trade shows and other customer facing activities increased significantly, as the prior year first quarter was affected by global

COVID-19

restrictions. Shipping expense increased 10% for the quarter, were positively impacted by lower costs inputs at the Company’s genomics operations and favorable product mix towards higher margin diagnostic and animal care products; this improvement was somewhat offset by lower sales of mycotoxin test kitsprimarily due to ~~a prior year outbreak of DON in corn crops~~rate increases and fuel surcharges from both small package and truckload shippers.

General and administrative expenses were $27.9 million in the ~~U.S.~~first quarter, and ~~western Europe,~~included $13.7 million in legal, consulting and other professional fees and expenses related to our combination with 3M’s Food Safety business, which ~~did not recur~~closed on September 1, 2022. After adjusting for these deal-related expenses, first quarter run rate general and administrative expenses were $14.2 million, an increase of $829,000, or 6%. The increase was primarily the result of incremental expense from acquisitions, including amortization, stock based compensation grants, and license fees relating to information technology infrastructure and software investments.

Research and development expense was $4.9 million in the ~~current~~first quarter of fiscal ~~year. Gross margin for the nine month period ended February 28, 2018 was 48.0%~~2023, an increase of $557,000, or 13%, compared to ~~47.6%~~the same period in the prior year. The increase was primarily the result of external costs for testing and validation for new commercial products in the Animal Safety segment, and to a lesser extent, compensation and other personnel related increases.

Operating Income

Operating income was $6.1 million in the first quarter of fiscal 2023, compared to $21.7 million in the same period of the prior year. Gross margins for the year to date were positively impacted by improved raw material costs at the Company’s genomics operations and favorable product mix towards higher margin diagnostic and animal care products; this improvement was somewhat offset by mix

changes resulting from the three most recent acquisitions (Rogama, Quat-Chem and Neogen Australasia), all of which have gross margins that are lower than the historical average for the Company, and lower sales of mycotoxin test kits due to a prior year outbreak of DON in corn crops in the U.S. and western Europe, which did not recur in the current fiscal year.

~~Operating Expenses~~

~~Operating expenses were $29.6 million in the third quarter, compared to $26.5 million in the same quarter of last fiscal year, an~~

increase of $3.1 million, or 12%. Sales and marketing expenses were $17.5 million, compared to $15.3 million in last year’s third quarter, an increase of 14%, primarily due to increases in salaries and related personnel costs, shipping expense, and higher advertising expenses in support of new product launches. General and administrative expense increased $700,000, or 9%, in the third quarter; increases in amortization of acquired intangible assets, IT consulting, and higher salary expenses were partially offset by lower stock based compensation expense resulting from forfeitures due to employee retirements and reduced legal expenses. In last year’s third quarter, the Company closed on two acquisitions, while there were none in this year’s third quarter. For the year to date period, research and development expense increased 7% in the third quarter to a total of $2.8 million. Increases were due to increases in compensation, higher depreciation resulting from investments in laboratory equipment, and projects relating to product improvements and new product development. For the year to date, research and development expenses increased 10%. Operating expenses for the nine month period were $90.3 million, an increase of $11.3 million, or 14% over the same period last fiscal year. The recent acquisitions accounted for $2.8 million of the increase.

~~Operating Income~~

~~Operating income was $15.9 million in the third quarter, an increase of $1.5 million, or 11%, compared to operating income of~~

~~$14.4 million in the prior year.~~ Expressed as a percentage of ~~revenue,~~sales, operating income was ~~16.6%~~4.6% for the first quarter of fiscal 2023 compared to ~~16.2% in last year’s~~

~~third quarter. The improvement in operating margin percentage~~16.9%, respectively, for the ~~comparative~~same period in the prior year. Adjusting for the costs resulting from the 3M transaction, operating income was $19.8 million, or 15.0%, for the first quarter of the 2023 fiscal year.

Other Income


	Three Months Ended August 31,
(dollars in thousands)	2022			2021
Interest income (net of expense)	$	969		$	203
Foreign currency transactions		(421	)		(151	)
Other		49			(70	)

Total Other Income	$	597		$	(18	)

The increase in interest income in the first three months of fiscal 2023, compared to the same period a year ago, was the result of improved yields on our marketable securities balances due to higher interest rates on fixed income investments. Other income or expense resulting from foreign currency transactions was the result of changes in the value of foreign currencies relative to the U.S. dollar in countries in which we operate.

Income Tax Expense

Income tax expense in the first quarter of fiscal 2023 was $1.5 million, an effective tax rate of 21.8%, compared to $4.7 million, an effective tax rate of 21.4%, in the same period of the prior year. For the first quarter of fiscal 2023, the primary difference between the statutory rate of 21% and the effective rates recorded is the impact of higher tax rates in international countries we do business in, and also state taxes. In both periods, there was minimal benefit from the exercise of stock options.

Net Income

Net income was $5.2 million in the first quarter of fiscal 2023, compared to $17.1 million in the same period in the prior year. The decline in earnings for the quarter was primarily the result of ~~higher gross margins offset somewhat by operating~~$13.7 million in legal, consulting, professional fees and other expenses ~~which rose more than~~from the 3M Food Safety transaction. Excluding those charges and adjusting to the effective tax rate, net income was $15.9 million.

Non-GAAP

Financial Measures

This report includes certain financial information for the Company that differs from what is reported in accordance with GAAP. These

non-GAAP

financial measures consist of EBITDA, Adjusted EBITDA and Adjusted EBITDA margin. These

non-GAAP

financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of the ~~overall revenue increase. For~~Company, and because these

non-GAAP

financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in industries the ~~nine months ended February 28, 2018,~~Company operates in.

EBITDA

We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income ~~was $50.3 million, an increase of $4.4 million, or 10%, compared to operating income of $45.9 million~~taxes). EBITDA also forms the basis for the ~~same period last year. Expressed~~measurement of Adjusted EBITDA (discussed below).

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted for stock-based compensation and certain transaction fees and expenses. We present EBITDA because it provides an understanding of underlying business performance by excluding the following:

Stock-based compensation

. We believe it is useful to exclude stock-based compensation to better understand the long-term performance of the respective core businesses and to facilitate comparison with the results of peer companies.

Certain transaction fees and expenses.

We exclude fees and expenses related to certain transactions because they are outside of Neogen’s underlying core performance.

Adjusted EBITDA margin

We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of ~~revenue, year~~total revenues. We present Adjusted EBITDA margin as a performance measure to ~~date~~analyze the level of Adjusted EBITDA generated from total revenue.

These

non-GAAP

financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net income (loss), operating income, ~~was 17.2% compared~~cash flow from operating activities or other measures of financial performance. This information does not purport to ~~17.5%~~represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen’s financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.

The use of the terms EBITDA, Adjusted EBITDA and Adjusted EBITDA margin may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the ~~prior year.~~

~~Other Income~~method of calculation.

These

non-GAAP

financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:

they do not reflect changes in, or cash requirements for, Neogen’s working capital needs;

they do not reflect Neogen’s tax expense or the cash requirements to pay taxes;

they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;

they do not reflect any cash requirements for future replacements of assets that are being depreciated and ~~Income Tax~~

~~Other income was $1.4 million~~amortized; and

they may be calculated differently from other companies in Neogen’s industries limiting their usefulness as comparative measures.

You should compensate for ~~both~~these limitations by relying primarily on the ~~third quarter~~financial statements of ~~fiscal 2018~~Neogen and using these

non-GAAP

financial measures only as a supplement to evaluate Neogen’s performance.

For each of these

non-GAAP

financial measures below, we are providing a reconciliation of the differences between the

non-GAAP

measure and the ~~same period in 2017. Components of other~~most directly comparable GAAP measure.

Reconciliation between net income ~~in this year’s third quarter included $525,000 of interest income, $360,000 from an insurance settlement, $179,000 in currency gains~~ and a $255,000 gain recorded on the settlement of contingent consideration related to the Quat-Chem acquisition. Last year’s fiscal third quarter included a gain on the settlement of a licensing agreement of $660,000, currency gains of $442,000,EBITDA and interest income of $271,000. For the year to date period in fiscal 2018, other income was $3.2 million, primarily comprised of $1.3 million of interest income, currency gains of $1.1 million, $360,000 from an insurance settlement, $255,000 gain recorded on the settlement of contingent consideration related to the Quat-Chem acquisition, and $78,000 of royalty income. For the same period in fiscal 2017, other income was $1.8 million, which included interest income of $691,000, gain on the settlement of a licensing agreement of $660,000, currency gains of $263,000, and royalty income of $79,000.

Income tax expense in the third quarter was $700,000, an effective tax rate of 4%, compared to prior year third quarter expense of $5.4 million, an effective tax rate of 34%. The Company recorded favorable tax adjustments totaling $2.9 million during the quarterAdjusted EBITDA is as the result of tax reform passed in the U.S. in December 2017. The tax reform reduced the statutory federal income tax rate from 35% to 21%, and also resulted in other adjustments to income tax expense. The Company will compute its income taxfollows:


	Three Months Ended August 31
(Dollars in thousands)	2022			2021
Net Income	$	5,209		$	17,077
Net income margin %		3.9	%		13.3	%
Provision for income taxes		1,450			4,650
Depreciation and amortization		5,729			5,682
Interest income, net		(969	)		(203	)

EBITDA	$	11,419		$	27,206
Stock-based compensation		1,867			1,690
Certain transaction fees and expenses		13,732			—

Adjusted EBITDA	$	27,018		$	28,896

Adjusted EBITDA margin %		20.4	%		22.5	%

Adjusted EBITDA decreased 6% for the ~~fiscal year ending May 31, 2018 using a blended Federal Tax Rate of 29.2%. Accordingly,~~ first and second quarter income previously subject to tax at the 35% Federal Tax Rate benefitted from the 29.2% Federal Tax Rate. As required by generally accepted accounting principles, the Company revalued its net deferred tax liabilities during the quarter to reflect the lower rate, resulting in a credit to income tax expense of $5.6 million. In addition, the Company was required to estimate its cumulative unrepatriated foreign earnings and profits and calculate tax owed on those earnings and profits during the third quarter. This tax was estimated at $2.7 million, and the amount was recorded as federal income tax expense; payment of the tax is permitted over an eight year period.

~~For the first nine~~three months of fiscal ~~2018, income tax expense was $7.9 million~~2023 compared to ~~$16.3 million in~~ the ~~prior year; the current year to date effective tax rate was 15%, compared to an effective tax rate~~first three months of ~~34% in the prior~~ fiscal year. For the year to date period, the lower effective rate is primarily the result of the tax reform passed in the U.S. in December 2017 as discussed in the preceding paragraph. Additionally, during the year the Company has recorded credits of $3.4 million to federal income tax expense for excess tax benefits from the exercise of stock options,2022, due to ~~the adoption of ASU2016-09;~~ refer to Note 5 of the Company’s Consolidated Financial Statements for further information. In the second quarter of fiscal 2018, an IRS examination of the Company’s federal income tax returns for fiscal years 2014, 2015 and 2016 was concluded. As a result of the favorable outcome of the audit, the Company reversed a total of $816,000 from its reserve for uncertain tax positions,operating expenses growth which ~~had been accrued in prior fiscal years, with a corresponding credit to federal income tax expense.~~

~~Net Income~~

~~Net income attributable to Neogen increased 61% from $10.3 million to $16.6 million for the three month period ended February 28,~~

2018. For the year to date period, net income was $45.6 million, a 46% increase over prior year net income of $31.3 million. Pre tax income increases of 10% for the quarter and 12% for the year to date were favorably impacted by the effects of tax reform, excess tax benefits from the exercise of stock options, and positive results from the IRS examination that concluded during the year’s second quarter.

exceeded revenue growth.

Financial Condition and Liquidity

The overall cash, cash equivalents and marketable securities position of ~~the Company~~Neogen was ~~$192.2~~$347.7 million at ~~February 28, 2018~~August 31, 2022, compared to ~~$143.6~~$381.1 million at May 31, ~~2017. Approximately $46.5~~2022. Cash flow from operating activities was negative $14.1 million ~~was generated from operations~~ during the first ~~nine~~three months of fiscal ~~2018.~~2023, the result of deal-related expenses, inventory increases, and $1.3 million on business acquisitions. Net cash proceeds of ~~$18.9 million~~$905,000 were realized from the exercise of stock options and issuance of shares under ~~the Company’s employee stock purchase plan~~our Employee Stock Purchase Plan during the ~~same period. The Company~~first three months of fiscal 2023. We spent ~~$16.3~~$13.0 million for property, equipment and other

non-current

assets ~~during~~in the first ~~nine~~three months of fiscal ~~2018.~~

~~Accounts~~2023, with a significant portion of expenditures on IT for items such as laptops and software related to the 3M Food Safety business.

Net accounts receivable balances were ~~$73.2~~$93.1 million at ~~February 28, 2018, an increase of $4.6 million, or 7%,~~August 31, 2022 compared to ~~$68.6~~$99.7 million at May 31, ~~2017, less than the increase in revenue. Days~~2022. Days’ sales outstanding, a measurement of the time it takes to collect receivables, were 6360 days at ~~February 28, 2018~~August 31, 2022, compared to 6062 days at May 31, ~~2017. All~~2022 and 59 days at August 31, 2021. We have continued to carefully monitor our customer ~~accounts are actively managed and no losses~~receivables during the

COVID-19

pandemic; to date, we have not experienced an appreciable increase in ~~excess of amounts reserved are currently expected.~~

bad debt write offs related to the pandemic.

Net inventory ~~balances were $77.5~~was $129.0 million at ~~February 28, 2018,~~August 31, 2022, an increase of ~~$4.4~~$6.7 million, ~~or 6%,~~ compared to ~~$73.1 million at~~a May 31, ~~2017.~~2022 balance of $122.3 million. The ~~Company actively monitors its~~higher inventory ~~and balances~~levels are primarily reflective of the ~~need for adequate product availability to minimize backorders with a desire to improve inventory turnover and efficiency levels. Formal programs~~inflationary pressures on raw material costs. Additionally, we have been ~~instituted~~increasing inventory levels in an effort to reduce the impact of higher freight costs and to prevent backorders, as vendor order fulfillment has been erratic and certain suppliers are requiring higher minimum order levels due to their capacity constraints.

On September 1, 2022, after the close of the first quarter of fiscal ~~2018~~2023, Neogen, 3M, and Garden Spinco, a newly formed subsidiary of 3M created to ~~improve inventory turnover.~~

~~Inflation~~carve out 3M’s Food Safety business, closed on the transaction which had previously been announced in December 2021, combining 3M’s Food Safety business with Neogen in a Reverse Morris Trust transaction.

On June 30, 2022, Garden SpinCo entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650.0 million and ~~changing prices are~~a five-year senior secured revolving facility in the amount of $150.0 million (collectively, the “Credit Facilities”), which became available in connection with the merger and related transactions. The loan facility was funded to Garden Spinco on August 31, 2022, and upon the effectiveness of the merger on September 1, 2022, became Neogen’s obligation. Financial covenants include maintaining specified levels of funded debt to EBITDA, and debt service coverage. Pricing for the term loan is term SOFR plus 235 basis points. The Credit Facilities, together with the Notes below, represent the financing incurred in connection with the merger of the 3M Food Safety business with Neogen’s.

In July 2022 Garden SpinCo closed on an offering of $350.0 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Garden SpinCo did not ~~expected~~receive any proceeds from the sale of the Notes by the selling securityholder. Prior to ~~have~~the distribution of the shares of Garden SpinCo’s common stock to 3M stockholders, the Notes were guaranteed on a ~~material effect on operations, as management believes it will continue to be successful in offsetting increased input costs with price increases and/or cost efficiencies.~~

~~Management believes that the Company’s existing cash and marketable securities balances at February 28, 2018 along with available borrowings~~senior unsecured basis by 3M. Upon consummation of such distribution, 3M was released from all obligations under its ~~credit facility~~guarantee. Upon the effectiveness of the merger on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.

In addition to the 3M transaction described above, our future cash ~~expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash~~generation and borrowing capacity may not be sufficient to meet ~~the Company’s~~ cash requirements to fund the operating business, repay debt obligations, commercialize products currently under development or ~~its~~execute our future plans to acquire ~~other organizations, technologies or~~additional businesses, technology and products that fit within ~~the Company’s mission statement.~~our strategic plan. Accordingly, ~~the Company~~we may be required, or may choose, to issue additional equity securities or enter into other financing arrangements for a portion of ~~its~~our future ~~financing~~capital needs.

PART I – FINANCIAL INFORMATION

~~Item 3.~~

~~Quantitative and Qualitative Disclosures About Market Risk~~

~~The Company has~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. ~~The Company’s~~Our primary interest rate risk is due to potential fluctuations of interest rates for ~~variable rate borrowings (no borrowings at February 28, 2018) and~~ short-term investments.

Foreign exchange risk exposure arises because ~~the Company markets~~we market and ~~sells its~~sell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. ~~The Company’s~~Our operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, ~~the~~ euro, ~~the~~Mexican peso, Brazilian real, ~~the Mexican peso, the~~ Chinese yuan, Australian dollar and to a lesser extent, the Thai baht, Japanese yen, South Korean won, Indian rupee, ~~the~~ Canadian dollar, Guatemalan quetzal, Argentine peso, Uruguayan peso and Chilean peso; there is also exposure to a change in exchange rate between the British pound sterling and the ~~Australian dollar.~~euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously ~~recognized revenues~~invoiced amounts can be positively or negatively affected by changes in exchange rates in the course of ~~collection can be affected positively or negatively by changes in exchange rates. The Company enters into forward contracts~~collection. We use derivative financial instruments to help ~~mitigate~~manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the ~~United States,~~U.S., located in Scotland, England, Ireland, Italy, Switzerland, Poland, Brazil, Mexico, Guatemala, Argentina, Uruguay, Chile, China, Thailand, Japan, Korea, India, Canada and Australia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Guatemalan quetzal, Argentine peso, Uruguayan peso, Chilean peso, Chinese yuan, Thai baht, Japanese yen, South Korean won, Indian rupee, Canadian dollar and Australian dollar, ~~respectively, and also transacts business throughout Europe in the euro. The Company’s~~respectively. Our investments in foreign subsidiaries are considered tolong-term. As discussed in ITEM 1A. RISK FACTORS of our Annual Report on Form

10-K

for the year ended May 31, 2022, our financial condition and results of operations could be ~~primarily long-term.~~

adversely affected by currency fluctuations.

The following table sets forth the potential loss in future earnings or fair values, resulting from hypothetical changes in relevant market rates or prices:


Risk Category	Hypothetical Change	August 31, 2022		Impact
(dollars in thousands)
Foreign Currency - Revenue	10% Decrease in exchange rates	$	4,309	Earnings
Foreign Currency - Hedges	10% Decrease in exchange rates		1,822	Fair Value
Interest Income	10% Decrease in exchange rates		97	Earnings

PART I – FINANCIAL INFORMATION

~~Item 4.~~

~~Controls and Procedures~~

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of ~~the Company’s~~our disclosure controls and procedures as of ~~February 28, 2018~~August 31, 2022 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive ~~Chairman~~Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls over Financial Reporting

No changes in our control over financial reporting were identified as having occurred during the quarter ended ~~February 28, 2018~~August 31, 2022 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.


		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Interim Consolidated Financial Statements (unaudited)		2

	Consolidated Balance Sheets – ~~February 28, 2018~~August 31, 2022 and May 31, ~~2017~~2022		2

	Consolidated Statements of Income – Three ~~and nine~~ months ended ~~February 28, 2018~~August 31, 2022 and ~~2017~~2021		3

	Consolidated Statements of Comprehensive Income – Three ~~and nine~~ months ended ~~February 28, 2018~~August 31, 2022 and ~~2017~~2021		4

	Consolidated ~~Statement~~Statements of Equity – ~~Nine~~Three months ended ~~February 28, 2018~~August 31, 2022 and 2021		5

	Consolidated Statements of Cash Flows – ~~Nine~~Three months ended ~~February 28, 2018~~August 31, 2022 and ~~2017~~2021		6

	Notes to Interim Consolidated Financial Statements – ~~February 28, 2018~~August 31, 2022		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

~~Item 3.~~	~~Quantitative and Qualitative Disclosures About Market Risk~~		20

Item 4. 3.	~~Controls~~Quantitative and ~~Procedures~~Qualitative Disclosures About Market Risk		2029

Item 4.	Controls and Procedures		29

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings		2130

Item 6.	Exhibits		2131

SIGNATURES			2232

	CEO Certification ~~of Principal Executive Officer~~

	CFO Certification ~~of Principal Financial Officer~~

	Section 906 Certification


	Three Months Ended
	August 31,
	2022			2021

Net income	$	5,209		$	17,077
Foreign currency translations		(11,133	)		(4,623	)
Unrealized loss on marketable securities, net of tax		(424	)		(206	)

Total comprehensive income (loss)	$	(6,348	)	$	12,248


3.1		Certificate of Amendment to Articles of Incorporation filed on October 11, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant’s Annual Report on Form 10-K filed on July 30, 2020).

3.2		Restated Articles of Incorporation, as amended on November 23, 2011 (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Quarterly Report on Form 10-Q filed December 30, 2011).

3.3		Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to Exhibit 3 filed with the Registrant’s Quarterly Report on Form 10-Q filed December 28, 2018).

3.4		Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on March 17, 2022).

3.5		Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on September 1, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

3.6		By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q filed April 14, 2000).

3.7		Amendment to the By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.1		Credit Agreement, dated as of June 30, 2022, among Garden SpinCo Corporation, as borrower, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, and joined thereto as of September 1, 2022 by Neogen Corporation, as a borrower (incorporated by reference to Exhibit 10.9 to Neogen’s Registration Statement on Form S-4 (Registration No. 333-263667), filed with the SEC on July 27, 2022).

31.1		Certification of Principal Executive Officer ~~pursuant to Rule13a-14(a).~~

31.2		Certification of Principal Financial Officer ~~pursuant to Rule13a-14(a).~~

32		Certification ~~pursuant~~Pursuant to 18 U.S.C. ~~section~~Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


~~Dated: March 29, 2018~~		/s/ John E. Adent
	John E. Adent
		~~/s/ James L. Herbert~~ President & Chief Executive Officer
		~~James L. Herbert~~
		~~Executive Chairman~~
		(Principal Executive Officer)


~~Dated: March 29, 2018~~

		/s/ Steven J. Quinlan
		Steven J. Quinlan
		Vice President & Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)


	February 28, 2018			May 31, 2017
	(Unaudited)			(Audited)
Assets
Current Assets
Cash and cash equivalents	$	82,066		$	77,567
Marketable securities (at fair value, which approximates cost)		110,089			66,068
Accounts receivable, less allowance of $1,750 and $2,000		73,209			68,576
Inventories, net		77,506			73,144
Prepaid expenses and other current assets		9,334			7,606

Total Current Assets		352,204			292,961
Property and Equipment, net		72,514			61,748
Other Assets
Goodwill		99,478			104,759
Othernon-amortizable intangible assets		15,011			14,323
Customer-based intangibles, net of accumulated amortization of $23,846 and $20,846 at February 28, 2018 and May 31, 2017		33,518			35,983
Othernon-current assets, net of accumulated amortization of $11,893 and $9,931 at February 28, 2018 and May 31, 2017		22,876			18,635

Total Assets	$	595,601		$	528,409

Liabilities and Equity
Current Liabilities
Accounts payable	$	19,654		$	16,244
Accrued compensation		5,469			5,002
Income taxes		960			936
Other accruals		11,210			13,820

Total Current Liabilities		37,293			36,002
Deferred Income Taxes		11,400			17,048
Non-Current Liabilities		4,973			3,602

Total Liabilities		53,666			56,652
Commitments and Contingencies (note 9)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.16 par value, 60,000,000 shares authorized, 51,583,085 and 50,932,489 shares issued and outstanding at February 28, 2018 and May 31, 2017, respectively		8,253			8,149
Additionalpaid-in capital		197,246			174,742
Accumulated other comprehensive loss		(5,303	)		(7,203	)
Retained earnings		341,459			295,926

Total Neogen Corporation Stockholders’ Equity		541,655			471,614
Non-controlling interest		280			143

Total Equity		541,935			471,757

Total Liabilities and Equity	$	595,601		$	528,409


	Three Months Ended					Nine Months Ended
	February 28,					February 28,
	2018		2017			2018			2017
Revenues
Product revenues	$	78,142	$	73,964		$	244,298		$	223,170
Service revenues		17,750		14,421			48,667			39,577

Total Revenues		95,892		88,385			292,965			262,747
Cost of Revenues
Cost of product revenues		40,352		38,816			124,785			113,241
Cost of service revenues		10,019		8,689			27,517			24,556

Total Cost of Revenues		50,371		47,505			152,302			137,797

Gross Margin		45,521		40,880			140,663			124,950

Operating Expenses
Sales and marketing		17,492		15,340			52,331			45,824
General and administrative		9,280		8,548			29,096			25,094
Research and development		2,836		2,641			8,901			8,087

Total Operating Expenses		29,608		26,529			90,328			79,005

Operating Income		15,913		14,351			50,335			45,945

Other Income
Interest income		524		271			1,322			690
Other income		844		1,105			1,913			1,098

Total Other Income		1,368		1,376			3,235			1,788

Income Before Taxes		17,281		15,727			53,570			47,733
Provision for Income Taxes		700		5,350			7,900			16,250

Net Income		16,581		10,377			45,670			31,483
Net (Income)/Loss Attributable toNon-Controlling Interest		5		(90	)		(70	)		(163	)

Net Income Attributable to Neogen	$	16,586	$	10,287		$	45,600		$	31,320

Net Income Attributable to Neogen Per Share
Basic	$	0.32	$	0.20		$	0.89		$	0.62

Diluted	$	0.32	$	0.20		$	0.88		$	0.61


							Accumulated
					Additional		Other						Non-
	Common Stock				Paid-in		Comprehensive			Retained			controlling
	Shares		Amount		Capital		Income (Loss)			Earnings			Interest		Total
Balance, May 31, 2017		50,932	$	8,149	$	174,742	$	(7,203	)	$	295,926		$	143	$	471,757
Issuance of shares under share-based compensation plan		631		101		21,456										21,557
Issuance of shares under employee stock purchase plan		20		3		1,048										1,051
Conversion of minority interest to retained earnings											(67	)		67		—
Net income for the nine months ended February 28, 2018											45,600			70		45,670
Other comprehensive income								1,900								1,900

Balance February 28, 2018		51,583	$	8,253	$	197,246	$	(5,303	)	$	341,459		$	280	$	541,935


	Three Months Ended February 28,				Nine Months Ended February 28,
	2018		2017		2018		2017
	(in thousands, except per share amounts)
Numerator for basic and diluted net income per share:
Net income attributable to Neogen	$	16,586	$	10,287	$	45,600	$	31,320
Denominator for basic net income per share:
Weighted average shares		51,537		50,746		51,253		50,438
Effect of dilutive stock options		700		633		761		723

Denominator for diluted net income per share		52,237		51,379		52,014		51,161

Net income attributable to Neogen per share:
Basic	$	0.32	$	0.20	$	0.89	$	0.62

Diluted	$	0.32	$	0.20	$	0.88	$	0.61


	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
	(in thousands)
As of and for the three months ended February 28, 2018
Product revenues to external customers	$	42,618	$	35,524	$	—		$	78,142
Service revenues to external customers		5,027		12,723		—			17,750

Total revenues to external customers		47,645		48,247		—			95,892
Operating income (loss)		8,258		8,493		(838	)		15,913
Total assets		188,075		215,371		192,155			595,601

As of and for the three months ended February 28, 2017
Product revenues to external customers	$	39,318	$	34,646	$	—		$	73,964
Service revenues to external customers		3,631		10,790		—			14,421

Total revenues to external customers		42,949		45,436		—			88,385
Operating income (loss)		7,403		7,743		(795	)		14,351
Total assets		183,419		215,243		108,636			507,298


				Weighted-
				Average
	Shares			Exercise Price
	(in thousands)
Options outstanding June 1, 2017		2,708		$	32.88
Granted		819			59.26
Exercised		(668	)		28.23
Forfeited		(144	)		37.31

Options outstanding February 28, 2018		2,715			41.75


	FY 2018	FY 2017
Risk-free interest rate	1.6%	1.2%
Expected dividend yield	0.0%	0.0%
Expected stock price volatility	27.7%	35.2%
Expected option life	4.0 years	4.0 years


	Three Months Ended August 31,				Increase/ (Decrease)			%
(in thousands)	2022		2021		Increase/ (Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	19,787	$	20,408	$	(504	)		(3	)%
Bacterial & General Sanitation		10,728		11,165		(437	)		(4	)%
Culture Media & Other		19,254		18,046		1,091			7	%
Rodent Control, Insect Control & Disinfectants		9,575		7,649		1,926			25	%
Genomics Services		5,299		5,454		(155	)		(3	)%

	$	64,643	$	62,722	$	1,921			3	%
Animal Safety
Life Sciences	$	1,589	$	1,363	$	226			17	%
Veterinary Instruments & Disposables		14,673		15,337		(664	)		(4	)%
Animal Care & Other		10,526		9,219		1,307			14	%
Rodent Control, Insect Control & Disinfectants		22,214		22,149		65			0	%
Genomics Services		18,704		17,515		1,189			7	%

	$	67,706	$	65,583	$	2,123			3	%

Total Revenues	$	132,349	$	128,305	$	4,044			3	%


	Three Months ended February 28,
					Increase/
	2018		2017		(Decrease)			%
			(in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues	$	16,807	$	16,453	$	354			2	%
Bacterial & General Sanitation		8,992		8,348		644			8	%
Dehydrated Culture Media & Other		10,511		10,383		128			1	%
Rodenticides, Insecticides & Disinfectants		7,359		5,040		2,319			46	%
Genomics Services		3,976		2,725		1,251			46	%

	$	47,645	$	42,949	$	4,696			11	%
Animal Safety
Life Sciences	$	2,769	$	2,332	$	437			19	%
Veterinary Instruments & Disposables		10,630		10,000		630			6	%
Animal Care & Other		7,535		6,311		1,224			19	%
Rodenticides, Insecticides & Disinfectants		14,590		16,111		(1,521	)		(9	)%
Genomics Services		12,723		10,682		2,041			19	%

	$	48,247	$	45,436	$	2,811			6	%

Total Revenues	$	95,892	$	88,385	$	7,507			8	%


	Nine Months ended February 28,
					Increase/
	2018		2017		(Decrease)			%
			(in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues	$	54,960	$	53,090	$	1,870			4	%
Bacterial & General Sanitation		27,435		25,340		2,095			8	%
Dehydrated Culture Media & Other		32,483		29,792		2,691			9	%
Rodenticides, Insecticides & Disinfectants		18,175		7,088		11,087			156	%
Genomics Services		10,887		7,757		3,130			40	%

	$	143,940	$	123,067	$	20,873			17	%
Animal Safety
Life Sciences	$	7,589	$	7,261	$	328			5	%
Veterinary Instruments & Disposables		32,804		29,281		3,523			12	%
Animal Care & Other		24,056		21,563		2,493			12	%
Rodenticides, Insecticides & Disinfectants		50,228		52,796		(2,568	)		(5	)%
Genomics Services		34,348		28,779		5,569			19	%

	$	149,025	$	139,680	$	9,345			7	%

Total Revenues	$	292,965	$	262,747	$	30,218			12	%